My doctor was of the opinion that over-medicalisation of patients was a common problem, and that a high PSA reading might ...
A new drug combo of enzalutamide and hormone therapy has been shown to extend survival for men with recurring prostate cancer, reducing death risk by over 40%. The study followed more than 1,000 ...
Swiss drugmaker Novartis said on Sunday its targeted radiotherapy treatment Pluvicto reduced the risk of progression or death ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results